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Abstract
Blocking neurotransmission, botulinum neurotoxin is the most poisonous biological substance known to mankind. Despite
its infamy as the scourge of the food industry, the neurotoxin is increasingly used as a pharmaceutical to treat an expanding
range of muscle disorders. Whilst neurotoxin expression by the spore-forming bacterium Clostridium botulinum appears
tightly regulated, to date only positive regulatory elements, such as the alternative sigma factor BotR, have been implicated
in this control. The identification of negative regulators has proven to be elusive. Here, we show that the two-component
signal transduction system CBO0787/CBO0786 negatively regulates botulinum neurotoxin expression. Single insertional
inactivation of cbo0787 encoding a sensor histidine kinase, or of cbo0786 encoding a response regulator, resulted in
significantly elevated neurotoxin gene expression levels and increased neurotoxin production. Recombinant CBO0786
regulator was shown to bind to the conserved 210 site of the core promoters of the ha and ntnh-botA operons, which
encode the toxin structural and accessory proteins. Increasing concentration of CBO0786 inhibited BotR-directed
transcription from the ha and ntnh-botA promoters, demonstrating direct transcriptional repression of the ha and ntnh-botA
operons by CBO0786. Thus, we propose that CBO0786 represses neurotoxin gene expression by blocking BotR-directed
transcription from the neurotoxin promoters. This is the first evidence of a negative regulator controlling botulinum
neurotoxin production. Understanding the neurotoxin regulatory mechanisms is a major target of the food and
pharmaceutical industries alike.
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Introduction
Botulinum neurotoxins are the most poisonous biological
substances known to mankind. The neurotoxins are metallopro-
teases which block neurotransmission in cholinergic nerves [1,2] in
humans and animals to cause botulism, a potentially lethal flaccid
paralysis. Botulinum neurotoxins are produced by vegetative
cultures of the anaerobic spore-forming bacterium Clostridium
botulinum which is widespread in the environment. The neurotoxins
can enter the victim’s body through intoxication with food or
drink, or they can be produced from spores germinating and
growing into active cultures in vivo, most likely in the gut of small
babies with poorly developed gut microflora or in deep wounds.
Despite their infamy, botulinum neurotoxins attract increasing
interest as a pharmaceutical to treat an expanding range of
muscular and other disorders [3,4], such as torticollis, focal
dystonia, inappropriate contraction of gastrointestinal sphincters,
eye movement disorders, hyperhidrosis, migraine [5], genitouri-
nary disorders [6], and even cancer [7]. Indications in cosmetic
surgery are well known.
Seven antigenically distinct toxin types (A to G), and several
subtypes therein, have been described [8–12]. Type A1 neuro-
toxins are the best characterized, a consequence both of their
frequent involvement in human botulism worldwide and of their
greater potency and, therefore, suitability for therapeutics [13].
Botulinum toxins are produced as a complex containing the
neurotoxin itself and one or more non-toxic auxiliary proteins that
protect the neurotoxin from environmental stress and assist in
absorption [14]. Type A1 toxins are complexed with the non-toxic
non-hemagglutinating (NTNH) protein and three hemagglutinins
(HA17, HA33 and HA70) [15–18]. A typical A1-type gene cluster
is transcribed in two operons, namely the ntnh-botA and ha operons
[19] (Figure 1). Both operons have consensus 210 and 235 core
promoter sequences, which are recognized by the alternative
sigma factor BotR, directing RNA polymerase (RNAP) to
transcribe the two operons [20]. The gene encoding BotR is
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located between the two operons within the neurotoxin gene
cluster.
Botulinum neurotoxin production is affected by the availability
of certain nutrients [21–23] and is associated with transition from
late-exponential to early-stationary phase cultures. A peak in the
level of neurotoxin gene cluster expression in late-exponential to
early-stationary phase cultures [19,24] suggests that neurotoxin
production is tightly regulated. To date only positive regulatory
elements have been implicated in this control. These include the
participation of BotR [25] and an Agr quorum sensing system
[26]. The identification of negative regulators of botulinum
neurotoxin production has until now proved to be elusive.
Two-component signal transduction systems (TCS) are con-
served in bacteria and differentially specialized to control a range
of cellular events in response to environmental stimuli. The
histidine kinases sense cellular or environmental signals through
the N-terminus of their sensor domains. This interaction leads to
autophosphorylation at a histidine residue in their C-terminus and
the subsequent activation of their cognate response regulator
present in the cytosol by transmission of the phosphoryl group to
an N-terminal aspartate residue of the response regulator and
further to the C-terminal output domain. Response regulators
possess DNA-binding activity, ultimately resulting in a specific
response in the expression of their target genes. The individual
roles of most TCSs in C. botulinum are not known, but their
involvement in control of virulence in other pathogenic bacteria
has been demonstrated [27]. Antisense mRNA inhibition of genes
encoding three TCSs caused decreased neurotoxin production in
C. botulinum type A strain Hall [28], suggesting these TCSs may
play a role in positive control of neurotoxin synthesis. The model
strain C. botulinum ATCC 3502 (Group I, type A) [29] encodes 29
putative TCSs and a set of orphan histidine kinases and response
regulators [30]. One of the intact TCSs, CBO0787/CBO0786
(Figure 1), shares over 90% amino acid identity with other C.
botulinum Group I strains and in many strains is located in the
vicinity of the neurotoxin genes (3.6 to 24 kilobases [kb] up- or
downstream of the toxin genes). Here we show that the TCS
CBO0787/CBO0786 negatively regulates botulinum neurotoxin
gene expression. Understanding the regulatory mechanisms that
control the production of botulinum neurotoxin is a major target
of the food and pharmaceutical industries.
Results
The cbo0787 and cbo0786 genes are down-regulated at
transition into stationary growth phase
We used quantitative reverse transcription PCR (qRT-PCR) to
measure the relative expression of cbo0787 and cbo0786 during the
growth of C. botulinum Group I type A strain ATCC 3502, which is
the most widely used model strain for genetic studies in C. botulinum
[26,31,32]. The relative transcription levels of cbo0787 and
cbo0786 followed an identical pattern, suggesting that the two
genes are co-transcribed (Figure 2). In relation to growth, cbo0787
and cbo0786 were expressed at a relatively constant level
throughout the logarithmic growth phase, and were down-
regulated at the transition into stationary phase (Figure 2).
Mutation of cbo0787 and cbo0786
To address the role of CBO0787/CBO0786, we constructed
single, insertional inactivation mutations in cbo0787 or cbo0786
using the ClosTron tool [33]. Single insertion of the group II
intron from pMTL007 into the desired sites in cbo0787 or cbo0786
(Figure 1) was confirmed by PCR (Figure 3A) and Southern
blotting (Figure 3B). Consecutive cultures showed the mutants to
be erythromycin resistant and stable. No significant difference
between the growth of the TCS mutants and the ATCC 3502
wild-type strain (WT) were observed (Figure 2), and the log cell
counts per ml of WT and the cbo0787 and cbo0786 mutant cultures
at early stationary phase (10 hours) were 8.9, 9.0 and 8.8,
respectively.
The cbo0787 or cbo0786 mutants show induced
expression of the neurotoxin cluster genes
We used qRT-PCR to measure the relative expression of botA
encoding botulinum neurotoxin type A and ha33 encoding one of
the three haemagglutinins in WT and the two TCS mutants at
mid-exponential, late exponential and early stationary growth
Figure 1. Schematic representation of the TCS CBO0787/CBO0786 and neurotoxin loci in C. botulinum ATCC 3502. The neurotoxin
operons are indicated with arrows. Predicted TCS domains are marked with gray color and the corresponding functions are listed under each gene.
Insertional sites of ClosTron mutagenesis in cbo0786 encoding a response regulator and cbo0787 encoding a sensor histidine kinase are indicated
with dashed lines.
doi:10.1371/journal.ppat.1003252.g001
Author Summary
Botulinum neurotoxin produced by the spore-forming
bacterium Clostridium botulinum is the most poisonous
biological substance known to mankind. By blocking
neurotransmission, the neurotoxin causes a flaccid paral-
ysis called botulism which may to lead to death upon
respiratory muscle collapse. Despite its infamy as the
scourge of the food industry, the neurotoxin is attracting
increasing interest as a pharmaceutical to treat an
expanding range of muscle disorders. Whilst neurotoxin
production by C. botulinum appears tightly regulated, to
date only positive regulatory elements, thus enhancing the
neurotoxin production, have been implicated in this
control. The identification of negative regulators, respon-
sible for down-tuning the neurotoxin synthesis, has proven
to be elusive, but would offer novel approaches both for
the production of safe foods and for the development of
therapeutic neurotoxins. Here, we report a two-compo-
nent signal transduction system that negatively regulates
botulinum neurotoxin production. Understanding the
neurotoxin regulatory mechanisms is a major target of
the food and pharmaceutical industries alike.
Botulinum Neurotoxin Repressor
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phases. The two genes were selected to represent the two operons
present in the neurotoxin gene cluster, and the three time points
used have been shown to associate with induction and repression
of the neurotoxin gene expression [19,34], while later time points
typically involve other cellular events, such as sporulation or lysis,
and were thus not considered relevant. As expected, the WT levels
of botA and ha33 expression peaked at late exponential or early
stationary growth phases (Figure 4). Strikingly, the cbo0787 mutant
had a maximum of 10.4-fold (P,0.01) and 8.0-fold (P,0.01)
higher relative botA and ha33 expression levels, respectively, than
the WT (Figure 4), the most prominent differences being observed
at early stationary growth phase. This suggests that the histidine
kinase CBO0787 is required to sense an as yet unidentified signal
for the efficient ‘switch-off’ of the neurotoxin gene expression at
transition into stationary growth phase.
The cbo0786 mutant also showed significantly increased botA
and ha33 expression levels in relation to WT (Figure 4). A
maximum of 2.4-fold (P,0.05) induction for botA at early
stationary phase and 3.8-fold (P,0.01) induction for ha33 at late
exponential growth phase were measured. These data suggest that
CBO0786 negatively regulates neurotoxin gene expression, either
directly or indirectly.
The cbo0787 or cbo0786 mutants show induced
neurotoxin production
To confirm that our findings at the transcription level apply to
protein level, we analyzed the relative amounts of botulinum
neurotoxin in the WT and mutant culture supernatants collected
at mid-exponential, late exponential and early stationary growth
phases. Measurements were made using an enzyme-linked
immunosorbent assay (ELISA). At mid-exponential growth phase,
neurotoxin production was slightly but not significantly increased
in the cbo0787 and cbo0786 mutant cultures compared to WT
culture (Figure 5A). At late exponential and early stationary
growth phases, neurotoxin production was significantly increased
(2.1 to 3.7-fold higher OD405 readings, P,0.05) in both the
cbo0787 and cbo0786 mutant cultures relative to WT culture
(Figure 5A). To validate this result, we complemented the cbo0786
mutation by introducing pMTL::cbo0787/0786, containing the
TCS genes and their putative native promoter, into the cbo0786
mutant and showed that neurotoxin levels in early-stationary
phase cultures were restored to the vector-only control (WT-
pMTL) level (P,0.05, Figure 5B). No difference was observed in
growth between the cbo0786-pMTL control and the complement-
ed strain (Figure 5C).
The CBO0786 response regulator binds to neurotoxin
promoters
To test the hypothesis that the TCS response regulator
CBO0786 is a transcriptional repressor of the neurotoxin gene
cluster in ATCC 3502, we examined the binding of the
recombinant CBO0786 protein to probes that encompassed the
intergenic region between ha33 and botR containing the promoter
of the ha operon [35] (Pha33 probe), or the intergenic region
between botR and ntnh containing the promoter of the ntnh-botA
operon [35] (Pntnh-botA probe), by electrophoretic mobility shift
assay (EMSA). CBO0786 caused a shift in the mobility of both
probes, although its binding affinity to the Pntnh-botA probe
appeared somewhat lower than to the Pha33 probe (Figure 6). The
specific nature of binding was further confirmed by disappearance
of both protein-DNA complexes using competition with a 200-fold
excess of unlabeled probe. Moreover, no electrophoretic shift was
observed with the negative control probe (Figure 6). EMSA with
Figure 3. Insertional inactivation of cbo0787 and cbo0786. (A) PCR analysis of mutations. Ll.LtrB intron insertion was detected with primers
flanking the insertional sites yielding a 2.3-kb PCR product in cbo0787 mutant and a 2.2-kb product in cbo0786 mutant (left), and with a gene-specific
primer and the intron-binding primer EBS universal yielding a 785-bp product in the cbo0787 mutant and a 260-bp product in the cbo0786 mutant
(right). (B) Southern blot analysis of HindIII digested genomic DNA from WT and cbo0787 and cbo0786 mutants with intron-specific probe.
doi:10.1371/journal.ppat.1003252.g003
Figure 2. Expression of cbo0787 and cbo0786 in C. botulinum
ATCC 3502 wild type (WT) and the growth curves of WT and
the cbo0787 and cbo0786 mutants. Quantitative RT-PCR analysis of
relative cbo0787 (light grey bars) and cbo0786 (dark grey bars) transcript
levels in WT. Target gene expression was normalized to 16S rrn and
calibrated to 2-hour time point. Growth of WT (line without symbols),
cbo0787 mutant (square) and cbo0786 mutant (diamond) in tryptose-
peptone-glucose-yeast extract medium. Arrows indicate sampling at
mid-exponential (ME), late exponential (LE) and early stationary (ES)
growth phases. Error bars represent standard deviations of three
replicate measurements.
doi:10.1371/journal.ppat.1003252.g002
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recombinant CBO0786 phosphorylated by acetyl phosphate
yielded a similar shift (Figure 7), indicating that phosphorylation
is not essential for CBO0786 binding to DNA in vitro. These results
suggest that CBO0786 recognizes and binds to the promoter
regions of the ha and the ntnh-botA operons.
To understand the DNA-binding specificity of CBO0786, we
identified its binding sites using DNase I footprinting and
fluorescently end-labeled Pha33 and Pntnh-botA probes (Figure 8).
With the Pha33 probe, the region protected by CBO0786 (251 bp
to 231 bp upstream of ha33 and 2196 bp to 2176 bp upstream
of botR) was present in both strands (Figures 8A and 8B). Greater
protection by CBO0786 was observed in the antisense strand
containing the promoter of the ha operon [35], suggesting that the
antisense sequence (TATGTTATATGTTATATGTAA,
Figure 8C) is the major CBO0786 binding site. Interestingly, the
core promoter 210 region (GTTATA) of the ha operon,
recognized by the alternative sigma factor BotR [20], appeared
as a direct repeat in the CBO0786 binding site, suggesting that
CBO0786 represses transcription of the ha operon by binding to its
core promoter.
In the Pntnh-botA probe, a site of CBO0786 protection similar to
that observed with the Pha33 probe was evident (Figures 8D and
8E). Both strands contained the same protection site
(GGCTATGTTATAT) (2120 bp to 2108 bp upstream of ntnh,
Figure 8F). Accordingly, the 210 region (GTTATA) of the ntnh-
botA operon core promoter was presented in the binding region,
but in one copy only. In accordance with the EMSA analysis, the
binding affinity of CBO0786 to the ntnh-botA promoter appeared
lower than to the promoter of the ha operon.
The CBO0786 response regulator represses in vitro
transcription from neurotoxin promoters
To demonstrate the direct effect of CBO0786 on transcription
of the neurotoxin genes, we carried out in vitro run-off transcription
assays using RNAP reconstituted with E. coli RNAP core enzyme
and the purified sigma factor BotR (Figure 9). DNA fragments
containing the promoter of the ha or ntnh-botA operons were cloned
and used as transcription templates. As expected, transcripts
produced from the promoters of ha or ntnh-botA operons were
observed only in the presence of both RNAP core enzyme and
BotR. Addition of increasing concentrations of recombinant
CBO0786 caused gradual inhibition of both transcripts, suggesting
CBO0786 directly represses the transcription from ha and ntnh-botA
promoters. Transcription from the ha promoter was more
efficiently repressed than that from the ntnh-botA promoter in the
presence of 4 mM CBO0786 (Figure 9). Taken together,
CBO0786 exhibits a higher binding affinity to the direct repeat
of the 210 region (GTTATA) in the ha promoter than in the ntnh-
botA promoter, and consequently shows a more effective inhibition
of in vitro transcription from the ha promoter than from the ntnh-
botA promoter. These results indicate that CBO0786 represses the
transcription of neurotoxin gene cluster by binding to the
consensus core promoter 210 region of ha and ntnh-botA operons.
To test whether CBO0786 represses the transcription of botR,
we also performed in vitro run-off transcription assays with DNA
template containing the botR promoter. No clear transcript from
botR promoter was observed in the presence of RNAP core with
BotR. Consistent with a previous study [20], the result demon-
strates that botR is not auto-transcribed in vitro.
Discussion
We show that the TCS CBO0787/CBO0786 negatively
regulates botulinum neurotoxin expression in C. botulinum Group
I type A1 strain ATCC 3502. This was supported by enhanced
toxin gene expression and increased toxin synthesis by cbo0787 and
cbo0786 mutants, by specific binding of recombinant CBO0786
regulator to the neurotoxin promoters, and recombinant
CBO0786 inhibiting in vitro transcription from the neurotoxin
promoters. Identification of botulinum neurotoxin repressors has
been an unattainable target of neurotoxin research for decades
[13,36,37], and would open up novel strategies for controlling the
public health risks caused by the toxin, but also for enhancing
industrial processes for therapeutic neurotoxin preparations.
While the current work focused on the most well-characterized
C. botulinum type A1 neurotoxin subtype, the role of CBO0787/
CBO0786 homologs in strains of other subtypes will be an
interesting line of future research. While the cbo0787/cbo0786
locus is found at an 11-kb distance from the neurotoxin gene
cluster (cbo0801–cbo0806) in ATCC 3502, a TCS showing a
strikingly high (.95%) amino acid identity to CBO0787/
CBO0786 is similarly encoded by loci near the neurotoxin gene
Figure 4. Disruption of cbo0787 or cbo0786 increased the
expression of neurotoxin genes. Quantitative RT-PCR analysis of
relative botA and ha33 transcript levels in WT and the cbo0786 and
cbo0787 mutants. RNA was isolated from cells at mid-exponential (ME),
late exponential (LE) and early stationary (ES) growth phases. Target
gene expression was normalized to 16S rrn and calibrated to WT at ME.
Error bars represent standard deviations of three replicate measure-
ments. Statistical significance of differences between WT and each
mutant is indicated with p-values (*, P,0.05; **, P,0.01).
doi:10.1371/journal.ppat.1003252.g004
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cluster in the genomes of type A2 strain Kyoto (3.6 kb distance),
type A5 strain H04402 065 (12 kb), and type F strain Langeland
(24 kb). This TCS, therefore, is an interesting candidate for a
universal neurotoxin repressor in Group I C. botulinum.
Our biochemical data suggest that CBO0786 recognizes and
binds to the consensus 210 region (GTTATA) of the ha and ntnh-
botA operon promoters. The 210 region is also specifically
recognized by the alternative sigma factor BotR [20,38],
Figure 6. CBO0786 binds to botulinum neurotoxin promoters in vitro. EMSA showing CBO0786 binding to Pha33 probe (left panel) and
Pntnh-botA probe (right panel). Specificity was confirmed using 200-fold molar excess of non-labeled competitor DNA and a random gene fragment
as negative control.
doi:10.1371/journal.ppat.1003252.g006
Figure 5. Neurotoxin ELISA to demonstrate elevated neurotoxin production by cbo0787 and cbo0787 mutants. (A) ELISA analysis of
botulinum neurotoxin in culture supernatants of WT and the cbo0786 and cbo0787 mutants at mid-exponential (ME), late exponential (LE) and early
stationary (ES) growth phases. The samples were diluted 1:10 at ME, 1:20 at LE, and 1:30 at ES. (B) ELISA analysis of botulinum neurotoxin in culture
supernatants of the vector-only control strains WT-pMTL and cbo0786-pMTL, and the complemented strain cbo0786-pMTL::cbo0787/0786 at ES. All
samples were diluted 1:30. (C) Growth curve of cbo0786-pMTL and cbo0786-pMTL::cbo0787/cbo0786. Error bars represent standard deviations of three
replicate measurements. Statistical significance of differences between WT and the two mutants is indicated with p-values (*, P,0.05; **, P,0.01).
doi:10.1371/journal.ppat.1003252.g005
Botulinum Neurotoxin Repressor
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suggesting that CBO0786 binding to the core promoter 210
region may prevent RNAP-BotR from binding and initiating the
transcription. The in vitro run-off transcription assay demonstrated
that CBO0786 directly inhibits RNAP-BotR-directed transcrip-
tion from the ha and ntnh-botA promoters, supporting the
hypothesis that CBO0786 inhibits the transcription of these
operons.
BotR is specifically required for botulinum neurotoxin gene
expression [25] but does not autoregulate its own expression [20].
While the 235 site (TTTACA) of the ha and ntnh-botA core
promoters is also found upstream of botR, the 210 site of botR
promoter is different (TTCGTA) [20]. Accordingly, we did not
observe CBO0786 binding to botR promoter. Moreover, we did
not find additional CBO0786 binding sites downstream of the botR
promoter in vitro or in silico. Thus it is plausible that CBO0786 does
not repress botR transcription.
While an early study detected both monocistronic botA and
bicistronic ntnh-botA mRNA species and a putative transcription
start site in the intergenic region between ntnh and botA [34], BotR
was later shown to exclusively drive the bicistronic form of
transcription [20]. Accordingly, we could not identify a CBO0786
binding site in the intergenic region between ntnh and botA, thus
inhibition by CBO0786 of transcription from a putative botA-
specific promoter is not likely.
BotR homologues in other pathogenic Clostridia, such as TetR
controlling tetanus neurotoxin in Clostridium tetani [39], TcdR
controlling toxins A and B in Clostridium difficile [40], and UviA
controlling bacteriocins in Clostridium perfringens [41] all recognize
the same 235 sequence as BotR [20]. Interestingly, TetR also
recognizes the same 210 box (GTTATA) as BotR [36]. The
closest homolog of CBO0787/CBO786 in C. tetani is CTC01420/
CTC01421, with the response regulator CTC01421 showing 75%
amino acid similarity to CBO0786. Thus CTC01420/CTC01421
may be an interesting candidate for a tetanus neurotoxin
repressor.
Our qRT-PCR and ELISA analysis, albeit yielding significantly
greater neurotoxin gene expression in both cbo0787 and cbo0786
mutants than in WT, suggest the mutant phenotypes to be
somewhat less striking than reported for some well-characterized
TCSs in other Gram-positive bacteria. For example, mutation of
CsrS, reported to respond to environmental Mg2+ [42] and to
repress virulence-related capsular polysaccharide production in
group A Streptococcus, resulted in a 10-fold increase in cellular
hyaluronic acid production in the presence of Mg2+ [42].
However, in medium lacking Mg2+, only a modest 1.5-fold
induction in hyaluronic acid production was observed [42]. Thus
the presence of the signal triggering a TCS kinase is a key to
control the activity of the cognate response regulator and its
subsequent effects on target gene expression. The signal triggering
CBO0787 and the role of phosphotransfer between CBO0787 and
CBO0786 remain to be elucidated. Although our EMSA analysis
suggested a DNA-binding activity for CBO0786 both with and
without phosphorylation in vitro, which is in line with reports on
some other TCS response regulators showing similar DNA-
binding properties regardless of phosphorylation state [43], in vivo
phosphorylation of CBO0786 could lead to conformational
changes that fine-tune its DNA binding affinity [44–46]. Identi-
fication of the signal triggering CBO0787 will be an important
future task for optimization of the study conditions to detect
maximal mutant phenotypes and thus to detect the maximal effect
of CBO0786 on neurotoxin repression.
The sensor domain of CBO0787 is predicted to contain an
extracellular loop consisting of 79 amino acid residues and is
flanked by two transmembrane helices, indicating that the signal
triggering it is most likely extracellular. Moreover, the increasing
differences observed between the relative neurotoxin gene
expression levels of the cbo0787 kinase mutant and WT towards
stationary growth phase are consistent with cell density-dependent
signals [37]. Neurotoxin overproduction associated with inability
to sporulate by strain Hall A-hyper [13] suggests that regulation of
these processes may be linked. Repression of toxin synthesis after
logarithmic growth before initiation of sporulation may represent a
survival mechanism when nutrient sources become limited.
Moreover, uncontrolled synthesis of botulinum neurotoxin would
waste energy since only nanogram quantities are sufficient for C.
botulinum to kill mammals and thereby gain nutrients and establish
anaerobiosis.
Previous studies have identified excess of arginine [21] and
tryptophan [22] to repress botulinum neurotoxin formation. By
contrast, glucose was shown to induce neurotoxin synthesis [21].
Interestingly, glucose has also been linked with regulation of toxin
synthesis in C. difficile through carbon catabolite control [47,48].
Further research will be required to clarify the mechanisms by
which nitrogen sources or glucose control neurotoxin synthesis in
C. botulinum; however, our preliminary data do not indicate that
these compounds trigger CBO0787 (data not shown). Thus it is
plausible that the regulation of neurotoxin synthesis is accom-
plished through a complex network and other regulators are
involved in this control.
While the relative neurotoxin gene expression levels in the
cbo0786 regulator mutant were significantly higher than those of
the WT at logarithmic growth phase, this difference was smaller at
early stationary growth phase. Moreover, the wild-type levels of
cbo0786 and cbo0787 transcription, being stable throughout the
logarithmic growth phase, collapsed at the transition into
stationary phase. These observations further support the involve-
ment of repressors other than CBO0786 in the ‘switching-off’ of
the neurotoxin expression, ensuring efficient onset of stationary-
phase cellular events.
Bearing in mind the emergence of repressor gene (tcdC)
mutations in ‘hyper-virulent’ isolates of the notorious healthcare-
associated pathogen C. difficile [49,50], the emergence of C.
botulinum strains with a mutated neurotoxin repressor would set
challenges to public health and safety. Hence identification of
neurotoxin regulators and their mutations is crucial.
In conclusion, we propose that the TCS CBO0787/CBO0786
negatively regulates botulinum neurotoxin gene transcription
through the response regulator CBO0786 blocking the 210 core
Figure 7. In vitro phosphorylated CBO0786 binds to Pha33 probe
in vitro. EMSA showing phosphorylated CBO0786 binding to Pha33 probe.
Specificity was confirmed using 200-fold molar excess of non-labeled
competitor DNA and a random gene fragment as negative control.
doi:10.1371/journal.ppat.1003252.g007
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promoter sites of the ha and ntnh-botA operons, inhibiting
transcription from the ha and ntnh-botA promoters. These data
provide keys for controlling the production of botulinum
neurotoxin, which is a major target of the food and pharmaceu-
tical industries.
Materials and Methods
Strains, culture, plasmids, and oligonucoleotides
Bacterial strains and plasmids are described in Table S1. C.
botulinum Group I type A1 strain ATCC 3502 [29] and derivative
mutants were grown in anaerobic tryptone-peptone-glucose-yeast
extract (TPGY) medium at 37uC under strictly anaerobic
conditions. Cell counts were determined by plating serially
diluted cultures on anaerobic TPGY agar plates. Escherichia coli
conjugation donor CA434 [51] and E. coli TOP10 strain
(Invitrogen) were grown in Luria-Bertani (LB) medium at 37uC.
When appropriate, growth media were supplemented with
100 mg/ml ampicillin, 50 mg/ml kanamycin, 25 mg/ml chloram-
phenicol, 250 mg/ml cycloserine, 15 mg/ml thiamphenicol or
2.5 mg/ml erythromycin. All oligonucleotide primers are listed in
Table S2.
Mutation of cbo0787 and cbo0786
Target genes were insertionally inactivated in C. botulinum
ATCC3502 by using the ClosTron system as previously reported
[33], in combination with the TargeTron gene knockout system kit
(Sigma-Aldrich). Target sites in cbo0786 (between nucleotides 267–
268) and cbo0787 (between nucleotides 603–604) were identified,
and intron-retargeting PCR primers (Table S2) were designed by
Figure 8. CBO0786 binds to the core promoter 210 region of the ha and ntnh-botA operons. DNase I footprinting analysis of 59-6-FAM
labeled sense strand (A, D) and 59-HEX labeled antisense strand (B, E) of Pha33 probe (A, B) and Pntnh-botA probe (D, E). Comparison of DNase I
digestion in the absence (blue peaks in A and D, green peaks in B and E) or with 10 mM of CBO0786 (red peaks). Protection regions are indicated by
square brackets. Protection regions are underlined in sequencing electropherograms of Pha33 probe (C) and Pntnh-botA probe (F) in the sense
strand. The consensus 210 regions of the ha and ntnh-botA promoters are indicated.
doi:10.1371/journal.ppat.1003252.g008
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using the TargeTron algorithm (http://www.sigma-genosys.com/
targetron/).
Plasmid retargeting was carried out as previously described [33]
and the resulting plasmid pMTL007::cbo0786 or pMTL007::cbo0787
was transferred to C. botulinum ATCC3502 by conjugation from E.
coliCA434 [51]. Successful transconjugants were screened on TPGY
agar plates containing cycloserine (250 mg/ml) and thiamphenicol
(15 mg/ml), and then resuspended in 1 ml of anaerobic TPGY
containing 1 mM isopropyl-b-D-thiogalactopyranoside (IPTG) and
thiamphenicol (7.5 mg/ml) and incubated at 37uC for 3 h. The
bacteria were then harvested, resuspended in 1 ml of fresh TPGY
and incubated for a further 3 h. The subsequent integrants were
selected by plating bacteria on TPGY agar supplemented with
erythromycin (2.5 mg/ml) and cycloserine (250 mg/ml) and incubat-
ed for 16 h at 37uC in anaerobic conditions to select clones
harboring the spliced erythromycin retrotransposition activated
marker (ErmRAM), which indicates intron integration.
To demonstrate the integration of the Ll.LtrB intron in the
desired sites, PCR was performed using primers flanking the target
sites in cbo0786 and cbo0787 (Table S2). PCR using ErmRAM
primers demonstrated the spliced ErmRAM. In addition, to
confirm that only a single intron insertion occurred in each
mutant, genomic DNA from the ATCC3502 wild-type strain and
mutants, and the pMTL007 plasmid DNA were digested
overnight with HindIII and analysed by Southern blot probed
with a DIG-labeled fragment derived from the Ll.LtrB intron
sequence.
Complementation of mutation
For complementation, a 2441-bp fragment encompassing
cbo0786, cbo0787, and the 59 noncoding region including their
putative promoter, was cloned into plasmid pMTL82151 [52] to
make pMTL::cbo0787/0786. pMTL::cbo0787/0786 or
pMTL82151 (empty-vector control) was transferred to C. botulinum
ATCC3502 or cbo0786 mutant by conjugation from E. coli CA434.
The complementation strain of cbo0786 mutant-pMTL::cbo0787/
0786 and control strains of C. botulinum ATCC3502-pMTL and
cbo0786 mutant-pMTL were obtained.
RNA isolation and qRT-PCR
Total RNA from C. botulinum ATCC 3502 and the two mutants
was isolated using the RNeasy Mini Kit (Qiagen) as described
[31]. Residual DNA was removed sequentially with RNase-free
DNase set (Qiagen) and the DNA-free Kit (Ambion) according to
the manufacturers’ instructions. The RNA was dissolved in 50 ml
of nuclease-free water (Sigma-Aldrich) and its concentration was
determined using the NanoDrop ND1000 spectrophotometer
(NanoDrop Technologies). The integrity of RNA was confirmed
with the Agilent Technologies 2100 Bioanalyzer.
For qRT-PCR, samples were collected during mid-exponential,
late exponential and early stationary growth phases (Figure 2).
Duplicate cDNA samples were generated from 800 ng of RNA
using the DyNAmo cDNA Synthesis Kit (Finnzymes). Quantita-
tive real-time PCR reactions comprised of 16 DyNAmo Flash
SYBR Green I Master Mix (Finnzymes), 0.5 mM of each primer
(Table S2), and 4 ml of 102-fold (cbo0786, cbo0787, botA, ha33) or
105-fold (16S rrn) diluted cDNA template in a total volume of
20 ul. All PCRs were performed in duplicate for both cDNA
replicates and three replicated experiments. Real-time PCR was
performed using the Rotor-Gene 3000 real-time thermal cycler
(Corbett Life Science). Cycling conditions included 7 minutes at
95uC, followed by 45 cycles of 95uC for 10 seconds and 60uC for
20 seconds, followed by 30 seconds at 60uC. PCR efficiencies
were determined based on a standard curve made from serially
diluted pooled cDNA for each primer pair. The calculated
efficiencies were 0.97 for 16S rrn, 0.99 for botA, 0.92 for ha33, 1.04
for cbo0787 and 0.93 for cbo0786. Melting curve analysis was
performed following the completion of the PCR to confirm
specificity of the PCR amplification products. Target gene
expression was normalized to the expression of 16S rrn based on
the Pfaffl method [53]. All samples were calibrated against the wild
type culture at mid-exponential growth phase.
Neurotoxin ELISA
Botulinum neurotoxin was quantified by using a commercial
type A neurotoxin ELISA kit (Tetracore) in three independent WT
and mutant culture supernatants collected at mid-exponential, late
Figure 9. CBO0786 represses transcription from ha and ntnh-botA promoters in vitro. Run-off transcription from ha33 and ntnh-botA
promoter-containing templates was repressed in the presence of increasing concentration of CBO0786. Arrow indicates the run-off transcripts.
doi:10.1371/journal.ppat.1003252.g009
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exponential, and early stationary growth phases [24,26,28]. The
plates were read at 405 nm (Multiskan Ascent, Thermo Fisher).
To keep the optical density readings in the dynamic range, the
culture supernatants were diluted 1:10 at mid-exponential, 1:20 at
late exponential, and 1:30 at early stationary growth phase.
Expression and purification of recombinant CBO0786 and
BotR
To construct the plasmids for the expression of N-terminal 6-
histidine translation fusion to the response regulator CBO0786 or
the alternative sigma factor BotR, PCR products were generated
using the primers listed in Table S2. The PCR products of cbo0786
and botR were digested with appropriate restriction enzymes and
cloned individually into plasmid pET28b (Novagen). The plasmids
were then individually transformed into E. coli Rosetta 2(DE3)
pLysS cells (Novagen).
CBO0786 expression was induced with 1 mM IPTG at 37uC
for 5 h. Cells from a 500-ml culture were harvested, re-suspended
in 10 ml of lysis/binding buffer (500 mM NaCl, 20 mM
imidazole, 20 mM Tris-HCl, pH 7.9) and lysed by sonication.
The lysate was centrifuged at 10 000 g for 15 min and filtered
through a 0.45-mm filter. The lysate was loaded with 1 ml of
Novagen His Bind affinity resin and allowed to bind for 30 min at
4uC. The resin was washed by 10 ml of lysis/binding buffer and
20 ml of wash buffer (500 mM NaCl, 60 mM imidazole, 20 mM
Tris-HCl, pH 7.9). Bound protein was eluted by washing with
4 ml of elution buffer (500 mM NaCl, 500 mM imidazole, 20 mM
Tris-HCl, pH 7.9).
BotR expression was induced with 1 mM IPTG overnight at
20uC and purified as described previously [20], with some
modifications. Briefly, cells were lysed by sonication in lysis/
binding buffer. The insoluble cell debris was separated by
centrifugation and dissolved in denaturing lysis/binding buffer
with 6 M guanidine hydrochloride. After centrifugation and
filtration, the denatured solubilized proteins were collected and
loaded onto column containing Ni-NTA affinity resin. The bound
proteins were let to refold on column with a decreasing urea
gradient (6 to 0 M) in lysis/binding buffer. Finally, the refolded
proteins were obtained by washing with elution buffer.
Eluted fractions were examined by SDS-PAGE and fractions
containing CBO0786 or BotR were pooled in the Novagen D-tube
Dialyzer and dialysed against 1 l of dialysis buffer (300 mM NaCl,
20% glycerol, 50 mM Tris-HCl, pH 8.0) overnight at 4uC.
Protein concentrations were determined by using the Bradford
reagent (Bio-Rad) and BSA (Sigma-Aldrich) was used as a
standard.
EMSA
A 354-bp fragment (Pha33 probe) covering the intergenic region
between ha33 and botR (2287 bp to 67 bp of ha33) and a 262-bp
fragment (Pntnh-botA probe) covering the intergenic region between
botR and ntnh (2210 bp to 52 bp of ntnh) were amplified by PCR
using 59-end biotin labeled primers (Table S2). CBO0786
phosphorylation by acetyl phosphate was performed as described
[54]. EMSA was performed with 1 nM of 59-end biotin labeled,
double-stranded oligonucleotide probes, 0 to 5.4 mM of recombi-
nant CBO0786, 1 mg of poly(dI-dC), 2.5% glycerol and 5 mM
MgCl2 in binding buffer (LightShift Chemiluminescent EMSA
Kit, Pierce). For competition assays, a 200-fold molar excess of
unlabeled double-stranded oligonucleotide was added. Binding
was allowed to proceed for 30 min at room temperature. Band
shifts were resolved on a 5% native polyacrylamide gel run in 0.56
TBE at 4uC for 1 h at 110 V.
DNase I footprinting
DNase I footprinting was performed in triplicate using a
modification of [55]. The Pha33 and Pntnh-botA probes were
amplified by PCR using 6-FAM-labeled forward primers and
HEX-labeled reverse primers (Table S2). Binding reactions were
performed as described for EMSA, with 20 nM of 59-6-FAM-
labeled probe and 10 mM protein in a final volume of 20 ml. After
20 min of incubation, DNA probes were partially digested by
0.002 to 0.2 Kunitz unit of DNase I (Sigma-Aldrich) for 5 min at
room temperature. Reactions were stopped by addition of 22 ml of
0.5 M EDTA and heated at 70uC for 10 min. The digested DNA
fragments were purified with the QIAquick PCR Purification Kit
(Qiagen) and eluted in 25 ml of water. The purified fragments were
separated in a capillary DNA analyzer (Applied Biosystems
31306l DNA Analyzer) and the electropherograms were analyzed
using the Peak Scanner software (Applied Biosystems). Protected
regions were identified by sequencing of the fragments using the
Thermo Sequenase Cycle Sequencing Kit (Affymetrix) and the
same labeled primers as described above (Table S2).
In vitro run-off transcription
The upstream region of the ha operon spanning the 2191 to
+185 sites relative to the transcription start, and the upstream
region of the ntnh-botA operon spanning the 2108 to +172 sites
relative to the transcription start, were cloned into pBluescript II
KS- (Stratagene) and then linearized by SpeI or PstI to produce
the run-off transcription templates. In vitro transcription assays
were carried out in 10-ml reaction mixtures, in the absence or
presence of CBO0786. E. coli RNAP core enzyme (Epicentre) was
preincubated for 30 min at 37uC with six-fold molar excess of
purified BotR. After incubation, 0.5 U RNAP, 0 to 4 mM of
recombinant CBO0786, and 15 nM of linearized plasmid DNA
were added in transcription buffer containing 40 mM Tris-HCl,
pH 8.0, 10 mM MgCl2, 50 mM KCl, 0.1 mg/ml BSA, 5%
glycerol, 4 U of RNasin (Promega), and incubated for 10 min at
37uC. Transcription was initiated by the addition of 200 mM
each of ATP, GTP and CTP, 50 mM of non-radioactive UTP
and 2.5 mCi [a-32P]-UTP (3000 Cimmol21, Perkin-Elmer). After
further incubation for 30 min at 37uC, the reaction was
quenched by adding 10 ml of RNA loading buffer (95%
formamide, 0.025% bromophenol blue, 0.025% xylene cyanol
FF, and 5 mM EDTA), followed by heating for 10 min at 80uC.
Samples were resolved by denaturing 6% PAGE and visualized
by autoradiography.
Statistical analysis
For any pairwise comparisons between the WT and one of the
two mutant strains, Student’s t-test was used. For a multiple
comparison among the cbo0786-pMTL::cbo0787/0786, cbo0786-
pMTL, and WT-pMTL, one-way ANOVA with Tukey’s post hoc
test was used.
The NCBI ID numbers of the genes and genome studied
cbo0787 (ID number 5185042), cbo0786 (ID number 5185041),
cbo0803, ha33 (ID number 5185058), cbo0805, ntnh (ID number
5185060), cbo0806, botA (ID number 5185061), Clostridium botulinum
type A strain ATCC 3502 genome (Accession number
NC_009495.1).
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